SG Americas Securities LLC Cuts Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

SG Americas Securities LLC cut its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 85.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,554 shares of the biotechnology company's stock after selling 37,638 shares during the period. SG Americas Securities LLC's holdings in ADMA Biologics were worth $112,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the last quarter. Geode Capital Management LLC lifted its stake in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock worth $107,606,000 after purchasing an additional 137,989 shares during the last quarter. Perpetual Ltd bought a new stake in ADMA Biologics in the fourth quarter worth $62,300,000. Assenagon Asset Management S.A. lifted its stake in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in ADMA Biologics in the third quarter worth $61,858,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.70% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Trading Down 1.1 %

Shares of NASDAQ:ADMA traded down $0.18 during midday trading on Friday, hitting $15.90. 1,740,737 shares of the stock traded hands, compared to its average volume of 2,383,370. The stock has a market capitalization of $3.76 billion, a PE ratio of 56.79 and a beta of 0.75. The business's 50 day moving average is $17.27 and its two-hundred day moving average is $17.84. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a one year low of $5.02 and a one year high of $23.64.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.